Paraneoplastic Neurological Syndrome
8
1
3
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
Metabolic Imaging for Diagnosis and Prognostication of Autoimmune encephalitiS
Diagnostic Performance of a Commercial Assay for the Detection of Neuronal Antibodies
Characterization of Immune-response in Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes
New Biomarkers in Auto-immune Encephalitis and Neurological Paraneoplastic Syndromes
Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden
HLA Analysis in Autoimmune Encephalitis and Related Disorders: Part II
Methylated DNA Detect in Paraneoplastic Syndrome of Nervous System
Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis